Arikayce’s Limited Population, Black Box Warning Won’t Limit Launch, Insmed Says
Executive Summary
Because it will be initially targeting specialists and a very sick population, the biotech thinks Arikayce will get early usage in its narrowly defined lung infection indication.
You may also be interested in...
AN2 Looks To Shift Gears On Phase III Epetraborole Trial On Potentially Lackluster Results
The company said it was pausing enrollment in the Phase III segment of its Phase II/III trial because of efficacy in MAC lung disease.
Variety Of Impacts COVID-19 Poses For Biopharma Reflected In Earnings Calls
Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.
Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue
Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.